• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蓄积的尿毒症毒素会削弱慢性肾脏病大鼠的骨力学性能。

Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease.

机构信息

Department of Health Sciences, Oita University of Nursing and Health Sciences, Oita 870-1201, Japan.

出版信息

Bone. 2013 Dec;57(2):477-83. doi: 10.1016/j.bone.2013.07.037. Epub 2013 Aug 3.

DOI:10.1016/j.bone.2013.07.037
PMID:23920356
Abstract

The prevalence of hip fracture is very high among patients with chronic kidney disease (CKD); however, the reason for this is unclear. We examined the effects of accumulated uremic toxins on bone chemical composition and elastic mechanical properties. Rats underwent thyroparathyroidectomy and progressive partial nephrectomy (TPTx-Nx), and were administered with vehicle or AST-120 to reduce serum indoxyl sulfate (IS) levels. Bone mechanical properties, bone mineral density (BMD), cortical bone chemical composition, and histomorphometry were determined. Storage modulus was reduced in TPTx-Nx rats compared with rats that underwent TPTx alone. BMD and histomorphometric parameters did not differ between the groups. In terms of cortical bone chemical composition, the mineral/matrix ratio and carbonate substitution was increased, whereas crystallinity was decreased in TPTx-Nx rats. The enzymatic crosslink ratio and pentosidine:matrix ratio were increased in TPTx-Nx rats. AST-120 abolished the effects of TPTx-Nx and decreased the serum IS concentration. Stepwise multiple regression analysis revealed that the pentosidine:matrix and mineral:matrix ratios were independent contributors to the storage modulus. In conclusion, the accumulated uremic toxins, including IS, seem to play an important role in deteriorating bone mechanical properties by altering the chemical composition of bone. This mechanism may account for the increased prevalence of hip fracture among patients with CKD.

摘要

慢性肾脏病(CKD)患者髋部骨折的患病率非常高;然而,其原因尚不清楚。我们研究了蓄积的尿毒症毒素对骨化学成分和弹性力学性能的影响。大鼠接受甲状腺切除术和进行性部分肾切除术(TPTx-Nx),并给予载体或 AST-120 以降低血清吲哚硫酸酯(IS)水平。测定骨力学性能、骨密度(BMD)、皮质骨化学成分和组织形态计量学。与单独 TPTx 大鼠相比,TPTx-Nx 大鼠的储存模量降低。两组之间的 BMD 和组织形态计量学参数没有差异。就皮质骨化学成分而言,TPTx-Nx 大鼠的矿物质/基质比和碳酸盐取代增加,而结晶度降低。TPTx-Nx 大鼠的酶交联比和戊糖素:基质比增加。AST-120 消除了 TPTx-Nx 的作用并降低了血清 IS 浓度。逐步多元回归分析显示,戊糖素:基质和矿物质:基质比是储存模量的独立贡献者。总之,蓄积的尿毒症毒素,包括 IS,似乎通过改变骨化学成分在骨力学性能恶化中起重要作用。这种机制可能解释了 CKD 患者髋部骨折患病率增加的原因。

相似文献

1
Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease.蓄积的尿毒症毒素会削弱慢性肾脏病大鼠的骨力学性能。
Bone. 2013 Dec;57(2):477-83. doi: 10.1016/j.bone.2013.07.037. Epub 2013 Aug 3.
2
Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease.与慢性肾脏病大鼠模型骨脆性相关的皮质骨化学成分变化。
Bone. 2011 Jun 1;48(6):1260-7. doi: 10.1016/j.bone.2011.03.672. Epub 2011 Mar 21.
3
Altered material properties are responsible for bone fragility in rats with chronic kidney injury.材料特性改变是慢性肾损伤大鼠骨脆性的原因。
Bone. 2015 Dec;81:247-254. doi: 10.1016/j.bone.2015.07.015. Epub 2015 Jul 15.
4
Uremic Toxicity and Bone in CKD.尿毒症毒素与慢性肾脏病中的骨骼
J Nephrol. 2017 Oct;30(5):623-627. doi: 10.1007/s40620-017-0406-x. Epub 2017 Jun 1.
5
A potential kidney-bone axis involved in the rapid minute-to-minute regulation of plasma Ca2+.一条参与血浆Ca2+快速逐分钟调节的潜在肾-骨轴。
BMC Nephrol. 2015 Mar 15;16:29. doi: 10.1186/s12882-015-0019-3.
6
Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice.中度慢性肾病会损害C57Bl/6J小鼠的骨质。
Bone. 2016 May;86:1-9. doi: 10.1016/j.bone.2016.02.006. Epub 2016 Feb 6.
7
Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.在低转换骨的肾衰竭大鼠模型中,甲状旁腺激素受体基因表达下调及成骨细胞功能障碍与骨骼对甲状旁腺激素抵抗相关。
Nephrol Dial Transplant. 2005 Sep;20(9):1904-11. doi: 10.1093/ndt/gfh876. Epub 2005 Jun 28.
8
Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease.在尿毒症性骨病实验模型中,奥帕膦酸盐治疗对骨体积和骨吸收的影响。
J Musculoskelet Neuronal Interact. 2005 Jun;5(2):174-81.
9
Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.慢性肾脏病诱导的继发性甲状旁腺功能亢进大鼠的钙敏感受体激动剂依替膦酸盐对骨骼健康的多尺度影响。
Bone. 2024 Aug;185:117126. doi: 10.1016/j.bone.2024.117126. Epub 2024 May 20.
10
Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.高转换率和低转换率慢性肾病中骨骼胶原交联和基质水合作用的变化
Osteoporos Int. 2015 Mar;26(3):977-85. doi: 10.1007/s00198-014-2978-9. Epub 2014 Dec 3.

引用本文的文献

1
Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.慢性肾脏病中的动力缺失性骨病:作为诊断和治疗靶点的潜在生物标志物的荟萃分析与叙述性综述
Ren Fail. 2025 Dec;47(1):2530162. doi: 10.1080/0886022X.2025.2530162. Epub 2025 Jul 16.
2
Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting.对于透析患者的骨质疏松症,地舒单抗是否是一种有效且安全的药物?关于在此背景下使用地舒单抗的考虑因素和最新进展。
Int Urol Nephrol. 2024 Oct;56(10):3285-3293. doi: 10.1007/s11255-024-04110-9. Epub 2024 Jun 10.
3
Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.
评估慢性肾脏病中的骨质疏松症:骨量和骨质量都很重要。
J Clin Med. 2024 Feb 9;13(4):1010. doi: 10.3390/jcm13041010.
4
Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats.特立帕肽和依替卡肽可改善慢性肾病模型大鼠的骨骼、纤维化及脂肪参数。
Osteoporos Sarcopenia. 2023 Dec;9(4):121-130. doi: 10.1016/j.afos.2023.11.002. Epub 2023 Dec 21.
5
Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices.慢性肾脏病 - 矿物质和骨异常(CKD-MBD)生物标志物在肾脏病诊疗实践中的实际应用。
Clin Kidney J. 2023 Nov 29;17(1):sfad290. doi: 10.1093/ckj/sfad290. eCollection 2024 Jan.
6
Inhibition of Indoxyl Sulfate-Induced Reactive Oxygen Species-Related Ferroptosis Alleviates Renal Cell Injury In Vitro and Chronic Kidney Disease Progression In Vivo.抑制硫酸吲哚酚诱导的活性氧相关铁死亡可减轻体外肾细胞损伤和体内慢性肾脏病进展
Antioxidants (Basel). 2023 Oct 30;12(11):1931. doi: 10.3390/antiox12111931.
7
Animal Models for Studying Protein-Bound Uremic Toxin Removal-A Systematic Review.研究蛋白结合型尿毒症毒素清除的动物模型:系统评价。
Int J Mol Sci. 2023 Aug 25;24(17):13197. doi: 10.3390/ijms241713197.
8
The Potential Influence of Uremic Toxins on the Homeostasis of Bones and Muscles in Chronic Kidney Disease.尿毒症毒素对慢性肾脏病骨骼和肌肉稳态的潜在影响。
Biomedicines. 2023 Jul 24;11(7):2076. doi: 10.3390/biomedicines11072076.
9
Effects of the uremic toxin indoxyl sulphate on human microvascular endothelial cells.尿毒症毒素吲哚硫酸酯对人微血管内皮细胞的影响。
J Appl Toxicol. 2022 Dec;42(12):1948-1961. doi: 10.1002/jat.4366. Epub 2022 Jul 25.
10
Research progress on the relationship between IS and kidney disease and its complications.IS 与肾脏疾病及其并发症关系的研究进展。
Int Urol Nephrol. 2022 Nov;54(11):2881-2890. doi: 10.1007/s11255-022-03209-1. Epub 2022 Apr 29.